Nephrogenic systemic fibrosis: A nephrologist's perspective

Hemodialysis International

Volumn 11, Issue SUPPL. 3, 2007, Pages

  Saab, Georges ^a   Cheng, Steven ^b  

^a University of Missouri   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Gadolinium; Nephrogenic system fibrosis

Indexed keywords

ALBUMIN; ERYTHROPOIETIN; FERRITIN; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; METHOTREXATE; SODIUM THIOSULFATE; STEROID; THALIDOMIDE;

ALBUMIN BLOOD LEVEL; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONSULTATION; DISEASE SEVERITY; DRUG MEGADOSE; FERRITIN BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; MEDICAL DECISION MAKING; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PLASMAPHERESIS; PUVA; RENAL REPLACEMENT THERAPY;

CONTRAST MEDIA; DECISION MAKING; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 34848901072     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2007.00222.x     Document Type: Conference Paper

References (29)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000; 356: 1000-1001.
2. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001; 23: 383-393.
3. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003; 139: 903-906.
4. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis. 2005; 46: 754-759.
5. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: An autopsy case and review of the literature. Arch Pathol Lab Med. 2006; 130: 209-212.
6. Cowper SE. Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol. 2003; 15: 785-790.
7. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006; 145: 234-235.
8. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006; 21: 1104-1108.
9. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006; 17: 2359-2362.
10. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology. 2007; 243: 148-157.
11. Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE. Nephrogenic systemic fibrosis: A review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol. 2007; 42: 139-145.
12. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis - A mysterious disease in renal failure patients: Role of gadolinium based contrast media in causation and the beneficial effect of IV sodium thiosulfate. Clin J Am Soc Nephrol. 2007; 2: 258-263.
13. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. Am J Roentgenol. 2007; 188: 586-592.
14. Centers for Disease Control and Prevention (CDC) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. Morb Mortal Wkly Rep. 2007; 56: 137-141.
15. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007; 56: 21-26.
16. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007; 56: 27-30.
17. Stenver DI. Investigation of the safety of MRI contrast medium Omniscan. Danish Medicines Agency. Available from: http://www.dkma.dk/1024/ visUKLSArtikel.asp?ArtikelID=8931
18. Thomsen HS. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol. 2006; 16: 2619-2621.
19. United States Food and Drug Administration. Medwatch - Public Health Advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance. Available from: http://www.fda.gov/cder/drug/advisory/ gadolinium_agents.htm
20. United Kingdom Medicines and Healthcare Products Regulatory Agency. Nephrogenic systemic fibrosis and gadolinium containing MRI contrast agents. Available from: http://www.mhra.gov.uk/home/idcplg?IdcService= SS_GET_PAGE&useSecondary=true&ssDocName= CON2030229&ssTargetNodeId=221
21. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol. 2003; 163: 993-1000.
22. Poggio ED, Nef PC, Wang X, et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis. 2005; 46: 242-252.
23. Skluzacek PA, Szewc RG, Nolan CR III, Riley DJ, Lee S, Pergola PE Prediction of GFR in liver transplant candidates. Am J Kidney Dis. 2003; 42: 1169-1176.
24. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998; 5: 491-502.
25. Lauchli S, Zortea-Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology. 2004; 208: 278-280.
26. Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol. 2005; 152: 531-536.
27. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003; 25: 204-209.
28. Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol. 2007; 3: 111-115.
29. DiCarlo JB, Gupta EA, Solomon AR. A pediatric case of nephrogenic fibrosing dermopathy: Improvement after combination therapy. J Am Acad Dermatol. 2006; 54: 914-916.